Overview

NVG-291 in Spinal Cord Injury Subjects

Status:
Recruiting
Trial end date:
2024-11-30
Target enrollment:
Participant gender:
Summary
A Single site (Shirley Ryan AbilityLab) Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
NervGen Pharma